
EG7 - Tough comps in a transition year

Redeye updates on EG7 post Q4-results which came in lower than expected, driven mainly by Big Blue Bubble which saw a faster revenue decline than we expected. On the back of this, we have adopted a more cautious view on 2024 while also lowering our 2025-26E forecasts somewhat. Still, we highlight that 2024 will be a transition year ahead of stronger growth in 2025-26E as ongoing growth investments starts to yield revenue.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[EG7 - Tough comps in a transition year](#)